企業プロフィール
Revelation Biosciences 株価・ニュース・カタリスト
- ティッカー:
- REVB
- 取引所:
- NASDAQ
- セクター:
- MedTech
- 所在地:
- United States
株価パフォーマンス
0.80 USD (-1.96%)
終値
最終更新: 2026年10月1日
4.14M USD
時価総額
株価変動の要因
2026年10月1日 時点で REVB は 1.96% 下落し、$0.8010 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Innate Immune Modulation Company
Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease. Its lead formulation activates Toll-like receptor 4 to produce a controlled innate immune response.
Gemini Lead Candidate
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide. Rather than broadly suppressing immunity, the candidate is designed to precondition and recalibrate the inflammatory response.
Acute Kidney Injury Program
The primary development program targets acute kidney injury associated with cardiac surgery. Revelation is preparing an adaptive pivotal study intended to evaluate prevention or reduction of clinically significant kidney injury.
Clinical and Preclinical Evidence
Gemini has been evaluated in Phase 1 studies and in preclinical models of acute kidney injury, chronic kidney disease, and infection. These data support selection of dose, timing, and endpoints for later-stage development.
Manufacturing Readiness
The company has initiated GMP manufacturing of Gemini and placebo for its planned clinical program. External manufacturers, a renal-focused contract research organization, and scientific advisers support execution.
今後のカタリスト
- Initiation of the adaptive pivotal Phase 2/3 study of Gemini in acute kidney injury in the fourth quarter of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。